<DOC>
	<DOCNO>NCT00041483</DOCNO>
	<brief_summary>The purpose study demonstrate Anecortave Acetate effective twelve month treatment photodynamic therapy ( PDT ) Visudyne patient eligible initial PDT treatment wet age-related macular degeneration .</brief_summary>
	<brief_title>Phase 3 Study Evaluate Anecortave Acetate vs. Visudyne Treatment Wet Form AMD</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Verteporfin</mesh_term>
	<mesh_term>Anecortave</mesh_term>
	<criteria>Patients race , either gender , age 50 year , diagnose subfoveal CNV due AMD best correct logMAR visual acuity 20/40 ( snellen equivalent ) 20/400 ( Snellen equivalent ) study eye . Clinically relevant concomitant disease exclude .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>AMD</keyword>
	<keyword>age-related macular degeneration</keyword>
	<keyword>Anecortave</keyword>
	<keyword>Acetate</keyword>
	<keyword>Wet form age-related macular degeneration</keyword>
</DOC>